Thao Vu
Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metabolomics | 6 | 2024 | 738 | 1.550 |
Why?
| | Magnetic Resonance Spectroscopy | 4 | 2022 | 627 | 1.130 |
Why?
| | Genome-Wide Association Study | 3 | 2025 | 1537 | 0.700 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 747 | 0.700 |
Why?
| | Algorithms | 6 | 2026 | 1849 | 0.600 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3926 | 0.530 |
Why?
| | Principal Component Analysis | 3 | 2023 | 192 | 0.510 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 348 | 0.500 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2025 | 2240 | 0.490 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1195 | 0.480 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 368 | 0.480 |
Why?
| | Mass Spectrometry | 1 | 2019 | 729 | 0.470 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2675 | 0.360 |
Why?
| | Computational Biology | 3 | 2025 | 678 | 0.330 |
Why?
| | Software | 2 | 2025 | 676 | 0.300 |
Why?
| | Discriminant Analysis | 2 | 2019 | 35 | 0.290 |
Why?
| | Computer Simulation | 2 | 2024 | 1014 | 0.280 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1792 | 0.220 |
Why?
| | 2S Albumins, Plant | 1 | 2025 | 31 | 0.220 |
Why?
| | Antigens, Plant | 1 | 2025 | 55 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 176 | 0.210 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2026 | 295 | 0.200 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.200 |
Why?
| | Entropy | 1 | 2023 | 45 | 0.200 |
Why?
| | Herpes Zoster Vaccine | 1 | 2025 | 154 | 0.200 |
Why?
| | Immunoglobulin E | 1 | 2025 | 315 | 0.190 |
Why?
| | Tryptophan | 1 | 2024 | 184 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 467 | 0.190 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 1 | 2022 | 20 | 0.190 |
Why?
| | Epitopes | 1 | 2025 | 479 | 0.190 |
Why?
| | Monocytes | 1 | 2025 | 538 | 0.190 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 441 | 0.190 |
Why?
| | Sample Size | 1 | 2023 | 124 | 0.180 |
Why?
| | Genomics | 2 | 2025 | 853 | 0.180 |
Why?
| | Decision Support Systems, Clinical | 1 | 2026 | 279 | 0.180 |
Why?
| | Herpesvirus 3, Human | 1 | 2025 | 342 | 0.180 |
Why?
| | Herpes Zoster | 1 | 2025 | 318 | 0.180 |
Why?
| | Artifacts | 1 | 2022 | 143 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 370 | 0.170 |
Why?
| | Machine Learning | 2 | 2025 | 594 | 0.170 |
Why?
| | Metabolome | 1 | 2024 | 390 | 0.160 |
Why?
| | Proportional Hazards Models | 1 | 2023 | 1331 | 0.150 |
Why?
| | Support Vector Machine | 1 | 2019 | 33 | 0.150 |
Why?
| | Least-Squares Analysis | 1 | 2019 | 73 | 0.150 |
Why?
| | Signal-To-Noise Ratio | 1 | 2018 | 71 | 0.140 |
Why?
| | Immunohistochemistry | 1 | 2022 | 1712 | 0.130 |
Why?
| | Humans | 15 | 2026 | 146342 | 0.130 |
Why?
| | Proteomics | 1 | 2024 | 1203 | 0.130 |
Why?
| | Smoking | 1 | 2024 | 1486 | 0.130 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 928 | 0.120 |
Why?
| | Pediatrics | 1 | 2025 | 1124 | 0.120 |
Why?
| | Clinical Competence | 1 | 2025 | 1272 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1543 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2022 | 3416 | 0.100 |
Why?
| | Internship and Residency | 1 | 2025 | 1281 | 0.100 |
Why?
| | Proteome | 1 | 2018 | 520 | 0.100 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 388 | 0.090 |
Why?
| | HIV Infections | 1 | 2025 | 3215 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2954 | 0.080 |
Why?
| | Sex Characteristics | 2 | 2024 | 801 | 0.070 |
Why?
| | Sex Factors | 2 | 2024 | 2107 | 0.070 |
Why?
| | Phenotype | 2 | 2025 | 3206 | 0.060 |
Why?
| | Vietnam | 1 | 2025 | 27 | 0.060 |
Why?
| | Vaccines, Synthetic | 1 | 2025 | 138 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2025 | 61 | 0.050 |
Why?
| | ROC Curve | 1 | 2026 | 617 | 0.050 |
Why?
| | Aged | 4 | 2025 | 26432 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 614 | 0.050 |
Why?
| | Peanut Hypersensitivity | 1 | 2025 | 143 | 0.050 |
Why?
| | Ultrasonography | 1 | 2026 | 788 | 0.050 |
Why?
| | Regression Analysis | 1 | 2025 | 999 | 0.040 |
Why?
| | Middle Aged | 4 | 2025 | 36619 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 481 | 0.040 |
Why?
| | Carbon Isotopes | 1 | 2022 | 143 | 0.040 |
Why?
| | Models, Genetic | 1 | 2025 | 540 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2025 | 509 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 319 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 539 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2025 | 2092 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2024 | 1298 | 0.040 |
Why?
| | Male | 5 | 2025 | 73396 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2025 | 568 | 0.040 |
Why?
| | Female | 5 | 2025 | 79499 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1879 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2025 | 844 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 996 | 0.040 |
Why?
| | Peptides | 1 | 2025 | 992 | 0.040 |
Why?
| | Protein Binding | 1 | 2025 | 2244 | 0.040 |
Why?
| | Liver | 1 | 2026 | 1864 | 0.030 |
Why?
| | Stroke | 1 | 2024 | 1287 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 6077 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8391 | 0.020 |
Why?
| | Infant | 1 | 2025 | 10114 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11913 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 14330 | 0.020 |
Why?
| | Adolescent | 1 | 2025 | 22557 | 0.010 |
Why?
| | Child | 1 | 2025 | 22693 | 0.010 |
Why?
| | Adult | 1 | 2025 | 41087 | 0.010 |
Why?
|
|
Vu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|